peoplePerson
Justin F. Gainor
Showed that oncogene-driven lung cancers respond poorly to immunotherapy and led the pivotal RET and ALK inhibitor studies.
Led the ARROW pralsetinib study and key analyses of ALK resistance and of PD-1 blockade in EGFR/ALK-positive lung cancer; directs thoracic cancers at MGH.
Role
Director, Center for Thoracic Cancers
Institution
Specialisms
ALK and ROS1 lung cancerImmunotherapy in oncogene-driven NSCLCRET
Profiles
| Title | Journal | Year |
|---|---|---|
| Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW) | Lancet Oncology | 2021 |
| EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer | Clinical Cancer Research | 2016 |
Pages like this
not linked directly; found by shared links- TrialARROW (thyroid cohorts)
Shares Pralsetinib, RET.
- TrialCROWN
Shares Lorlatinib, ALK, Non-small-cell lung cancer.
- PersonDaniel A. Haber
Shares Massachusetts General Hospital Cancer Center, Non-small-cell lung cancer.
- InstitutionShanghai Chest Hospital
Shares RET, Lorlatinib, ALK, Non-small-cell lung cancer.
- PersonBenjamin Solomon
Shares Lorlatinib, ALK, Non-small-cell lung cancer.
- PersonDong-Wan Kim
Shares Lorlatinib, ALK, Non-small-cell lung cancer.
- ProductEnsartinib
Shares ALK, Non-small-cell lung cancer.
- PairingSequence: targeted therapy before immunotherapy in driver-positive NSCLC
Shares RET, Lorlatinib, ALK, Non-small-cell lung cancer.